PDCD1 and neoplasm: CTLA4+ TAMs are systemically expanded in mouse and human CRC metastatic settings, and facilitate tumor progression and metastasis directly by generating lipid droplets in tumor cells, and also indirectly by inducing immune exhaustion, leading to anti-PD1 resistance (183).